Clopidogrel and Proton-Pump Inhibitors after Myocardial Infarction

PPI use was not associated with excess risk for adverse cardiovascular events or mortality in clopidogrel-treated patients, regardless of their CYP2C19 genotype.

The potential adverse interaction between clopidogrel and proton-pump inhibitors (PPIs) has been a topic of much concern (JW Gastroenterol May 21 2010). In fact, the FDA recently reiterated an advisory warning about the risk of adverse cardiovascular events associated with the concomitant use of clopidogrel and the PPI omeprazole. However, a recent prospective, randomized, placebo-controlled trial reported no significant risk for excess cardiovascular-related death, MI, or stroke in-hospital among patients receiving clopidogrel and omeprazole at 1 year (JW Gastroenterol Feb 25 2011). Moreover, a recent expert consensus document from the American College of Cardiology (ACC), the American College of Gastroenterology (ACG), and the American He…

Reviewing Author

David A. Johnson, MD

Disclosures

Consultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries

EquityCRH Medical Corporation

Editorial boardsMedscape Gastroenterology

Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors

David A. Johnson, MD

Disclosures

Consultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries

EquityCRH Medical Corporation

Editorial boardsMedscape Gastroenterology

Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors

Clopidogrel and Proton-Pump Inhibitors after Myocardial Infarction

Topics

Reviewing Author